Pacira BioSciences (PCRX)
Pacira BioSciences on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
4.3M
Short interest
settlement 2026-10-15
1.1
Days to cover
-14.0 days vs prior
25.4%
Short share of volume
2026-11-02
16,029
Fails to deliver
settlement 2026-10-09
Thu 5 Nov
Next earnings
estimated date
-$289K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in PCRX is 4,260,076 shares, down 3,301,077 shares over the last month. Over the last 48 readings it ranged from 4,260,076 shares (15 October 2026) to 8,474,359 shares (27 February 2026). The latest reading sits at the bottom of that range. At the reported average volume of 3.9M shares a day that is 1.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/pcrx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 4,260,076 | -47.3% | 3,933,128 | 1.08 |
| 2026-09-30 | 8,076,461 | +6.8% | 536,467 | 15.05 |
| 2026-09-15 | 7,561,153 | +3.2% | 582,564 | 12.98 |
| 2026-08-31 | 7,328,377 | +0.4% | 432,362 | 16.95 |
| 2026-08-14 | 7,297,363 | +1.2% | 902,817 | 8.08 |
| 2026-07-31 | 7,212,032 | +3.6% | 538,752 | 13.39 |
| 2026-07-15 | 6,963,375 | +5.7% | 441,184 | 15.78 |
| 2026-06-30 | 6,587,848 | +5.0% | 565,399 | 11.65 |
| 2026-06-15 | 6,276,888 | -4.8% | 376,108 | 16.69 |
| 2026-05-29 | 6,596,044 | -5.6% | 469,036 | 14.06 |
| 2026-05-15 | 6,987,520 | -10.3% | 680,534 | 10.27 |
| 2026-04-30 | 7,790,589 | +5.4% | 547,482 | 14.23 |
| 2026-04-15 | 7,391,141 | -8.3% | 470,624 | 15.70 |
| 2026-03-31 | 8,059,032 | -4.6% | 796,232 | 10.12 |
| 2026-03-13 | 8,448,571 | -0.3% | 838,608 | 10.07 |
| 2026-02-27 | 8,474,359 | +10.3% | 916,314 | 9.25 |
| 2026-02-13 | 7,684,573 | -2.5% | 704,187 | 10.91 |
| 2026-01-30 | 7,881,129 | +10.8% | 938,048 | 8.40 |
| 2026-01-15 | 7,111,947 | -3.3% | 1,163,471 | 6.11 |
| 2025-12-31 | 7,357,458 | +0.2% | 812,072 | 9.06 |
| 2025-12-15 | 7,343,873 | +1.7% | 835,302 | 8.79 |
| 2025-11-28 | 7,220,261 | -0.8% | 671,780 | 10.75 |
| 2025-11-14 | 7,276,394 | -0.1% | 904,436 | 8.05 |
| 2025-10-31 | 7,282,190 | +22.5% | 548,395 | 13.28 |
| 2025-10-15 | 5,946,077 | -5.4% | 493,651 | 12.05 |
| 2025-09-30 | 6,284,822 | -6.0% | 515,113 | 12.20 |
| 2025-09-15 | 6,685,410 | +1.2% | 647,290 | 10.33 |
| 2025-08-29 | 6,608,026 | +5.1% | 607,923 | 10.87 |
| 2025-08-15 | 6,288,411 | +10.4% | 976,060 | 6.44 |
| 2025-07-31 | 5,694,160 | +4.3% | 587,565 | 9.69 |
| 2025-07-15 | 5,461,498 | -2.5% | 505,898 | 10.80 |
| 2025-06-30 | 5,602,013 | +0.1% | 514,206 | 10.89 |
| 2025-06-13 | 5,599,189 | -4.0% | 602,150 | 9.30 |
| 2025-05-30 | 5,834,007 | +2.7% | 719,125 | 8.11 |
| 2025-05-15 | 5,679,155 | -7.6% | 989,026 | 5.74 |
| 2025-04-30 | 6,147,670 | +1.4% | 750,264 | 8.19 |
| 2025-04-15 | 6,060,462 | +2.1% | 1,204,253 | 5.03 |
| 2025-03-31 | 5,934,152 | +0.1% | 975,703 | 6.08 |
| 2025-03-14 | 5,931,023 | +1.2% | 805,942 | 7.36 |
| 2025-02-28 | 5,859,658 | +10.5% | 893,127 | 6.56 |
| 2025-02-14 | 5,304,071 | +3.1% | 686,717 | 7.72 |
| 2025-01-31 | 5,143,923 | -5.5% | 965,154 | 5.33 |
| 2025-01-15 | 5,444,817 | +24.8% | 768,497 | 7.09 |
| 2024-12-31 | 4,364,176 | -8.1% | 801,676 | 5.44 |
| 2024-12-13 | 4,750,188 | -0.9% | 1,025,995 | 4.63 |
| 2024-11-29 | 4,795,767 | -0.6% | 515,204 | 9.31 |
| 2024-11-15 | 4,822,169 | -11.7% | 605,528 | 7.96 |
| 2024-10-31 | 5,462,899 | -11.0% | 468,231 | 11.67 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of PCRX volume is 25.4%, down 4.6 points over the last five sessions. Over the last 30 readings it ranged from 14.7% (22 October 2026) to 81.1% (23 September 2026). The latest reading is 19.8 points below the 30-session average of 45.2%, on 299K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 76K | 299K | 25.4% | 0 |
| 2026-10-30 | 141K | 365K | 38.5% | 0 |
| 2026-10-29 | 31K | 104K | 30.1% | 0 |
| 2026-10-28 | 79K | 376K | 21.1% | 524 |
| 2026-10-27 | 27K | 172K | 15.8% | 0 |
| 2026-10-26 | 36K | 119K | 30.0% | 132 |
| 2026-10-23 | 36K | 210K | 17.0% | 1,100 |
| 2026-10-22 | 56K | 379K | 14.7% | 0 |
| 2026-10-21 | 187K | 689K | 27.1% | 100 |
| 2026-10-20 | 94K | 611K | 15.3% | 0 |
| 2026-10-19 | 82K | 349K | 23.5% | 0 |
| 2026-10-16 | 134K | 276K | 48.3% | 0 |
| 2026-10-15 | 183K | 769K | 23.9% | 792 |
| 2026-10-14 | 253K | 637K | 39.8% | 0 |
| 2026-10-13 | 340K | 629K | 54.1% | 3,006 |
| 2026-10-12 | 394K | 764K | 51.6% | 1,325 |
| 2026-10-09 | 1.1M | 2.4M | 44.7% | 637 |
| 2026-10-08 | 5.4M | 11.3M | 47.5% | 10,687 |
| 2026-10-07 | 280K | 351K | 79.8% | 0 |
| 2026-10-06 | 141K | 182K | 77.3% | 321 |
| 2026-10-05 | 125K | 184K | 68.0% | 0 |
| 2026-10-02 | 109K | 168K | 65.0% | 0 |
| 2026-10-01 | 84K | 146K | 57.4% | 0 |
| 2026-09-30 | 114K | 175K | 65.0% | 600 |
| 2026-09-29 | 78K | 141K | 55.2% | 0 |
| 2026-09-28 | 86K | 137K | 62.7% | 0 |
| 2026-09-25 | 52K | 152K | 34.5% | 0 |
| 2026-09-24 | 144K | 192K | 75.0% | 0 |
| 2026-09-23 | 123K | 152K | 81.1% | 0 |
| 2026-09-22 | 65K | 98K | 66.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in PCRX is 16,029 shares, up 15,986 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (12 March 2026) to 16,029 shares (9 October 2026). The latest reading sits at the top of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 16,029 | $36.39 | $583K |
| 2026-09-23 | 43 | $24.70 | $1K |
| 2026-09-18 | 2,507 | $24.48 | $61K |
| 2026-09-17 | 1,357 | $24.91 | $34K |
| 2026-09-01 | 45 | $25.90 | $1K |
| 2026-08-31 | 45 | $25.76 | $1K |
| 2026-08-28 | 45 | $25.83 | $1K |
| 2026-08-25 | 163 | $24.86 | $4K |
| 2026-08-12 | 1 | $24.38 | $24 |
| 2026-08-10 | 32 | $25.02 | $801 |
| 2026-08-04 | 1,012 | $26.92 | $27K |
| 2026-07-24 | 13,992 | $25.93 | $363K |
| 2026-07-08 | 183 | $25.82 | $5K |
| 2026-06-30 | 15 | $25.09 | $376 |
| 2026-06-17 | 4,890 | $22.82 | $112K |
| 2026-06-15 | 133 | $22.99 | $3K |
| 2026-06-03 | 8 | $22.25 | $178 |
| 2026-06-01 | 9,875 | $23.22 | $229K |
| 2026-05-19 | 58 | $22.44 | $1K |
| 2026-05-13 | 5,297 | $22.84 | $121K |
| 2026-04-23 | 291 | $24.88 | $7K |
| 2026-03-26 | 3 | $23.49 | $70 |
| 2026-03-25 | 3 | $23.20 | $70 |
| 2026-03-23 | 19 | $22.11 | $420 |
| 2026-03-20 | 4 | $22.57 | $90 |
| 2026-03-19 | 7 | $22.02 | $154 |
| 2026-03-17 | 908 | $22.69 | $21K |
| 2026-03-16 | 4 | $23.26 | $93 |
| 2026-03-13 | 14,482 | $23.53 | $341K |
| 2026-03-12 | 1 | $22.83 | $23 |
Insider trades
SEC Form 4, newest first. JSONInsiders at PCRX reported 2 open-market sells worth $289K in the last 90 days and no open-market buys. Latest filing: RIKER LAUREN (Senior Vice President, Finance) on 2026-10-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | RIKER LAUREN | Senior Vice President, Finance | Sell | 6K | $36.32 | $218K | 62K |
| 2026-10-08 | RIKER LAUREN | Senior Vice President, Finance | Exercise or conversion | 6K | $32.35 | $194K | 68K |
| 2026-08-17 | SLONIN JONATHAN | Chief Medical Officer | Sell | 3K | $23.23 | $71K | 216K |
| 2026-06-11 | RIKER LAUREN | Senior Vice President, Finance | Sell | 6K | $23.50 | $144K | 62K |
| 2026-06-10 | Brege Laura | Director | Grant | 6K | $0.00 | $0 | 30K |
| 2026-06-10 | Froimson Mark | Director | Grant | 6K | $0.00 | $0 | 27K |
| 2026-06-10 | BIGAL MARCELO | Director | Grant | 6K | $0.00 | $0 | 18K |
| 2026-06-10 | YANG MICHAEL J. | Director | Grant | 6K | $0.00 | $0 | 20K |
| 2026-06-10 | Young Alethia | Director | Grant | 6K | $0.00 | $0 | 18K |
| 2026-06-10 | CHRISTIE CHRISTOPHER | Director | Grant | 6K | $0.00 | $0 | 23K |
| 2026-06-10 | Hirawat Samit | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-06-04 | WILLIAMS KRISTEN | Chief Administrative Officer | Sell | 10K | $22.27 | $228K | 167K |
| 2026-06-03 | RIKER LAUREN | Senior Vice President, Finance | Tax withholding | 3K | $22.32 | $71K | 68K |
| 2026-06-03 | SLONIN JONATHAN | Chief Medical Officer | Tax withholding | 5K | $22.32 | $106K | 219K |
| 2026-06-03 | WILLIAMS KRISTEN | Chief Administrative Officer | Tax withholding | 9K | $22.32 | $190K | 177K |
| 2026-04-23 | Cross Shawn | Chief Financial Officer | Sell | 13K | $25.16 | $326K | 105K |
| 2026-04-23 | Cross Shawn | Chief Financial Officer | Exercise or conversion | 13K | $16.45 | $213K | 118K |
| 2026-04-22 | Cross Shawn | Chief Financial Officer | Sell | 2K | $25.01 | $38K | 105K |
| 2026-04-22 | Cross Shawn | Chief Financial Officer | Exercise or conversion | 2K | $16.45 | $25K | 107K |
| 2026-04-21 | Cross Shawn | Chief Financial Officer | Sell | 3K | $25.01 | $71K | 105K |
| 2026-04-21 | Cross Shawn | Chief Financial Officer | Exercise or conversion | 3K | $16.45 | $47K | 108K |
| 2026-04-20 | Cross Shawn | Chief Financial Officer | Sell | 8K | $25.14 | $194K | 105K |
| 2026-04-20 | Cross Shawn | Chief Financial Officer | Exercise or conversion | 8K | $16.45 | $127K | 113K |
| 2026-03-17 | SLONIN JONATHAN | Chief Medical Officer | Sell | 3K | $22.82 | $74K | 224K |
| 2026-03-17 | Froimson Mark | Director | Sell | 500 | $21.81 | $11K | 20K |
| 2026-02-11 | WILLIAMS KRISTEN | Chief Administrative Officer | Grant | 55K | $0.00 | $0 | 186K |
| 2026-02-11 | Teehan Brendan | Chief Commercial Officer | Grant | 52K | $0.00 | $0 | 101K |
| 2026-02-11 | RIKER LAUREN | Senior Vice President, Finance | Grant | 19K | $0.00 | $0 | 72K |
| 2026-02-11 | SLONIN JONATHAN | Chief Medical Officer | Grant | 55K | $0.00 | $0 | 227K |
| 2026-02-11 | Lee Frank D. | Chief Executive Officer | Grant | 262K | $0.00 | $0 | 661K |
| 2026-02-11 | Cross Shawn | Chief Financial Officer | Grant | 49K | $0.00 | $0 | 105K |
| 2026-02-02 | RIKER LAUREN | Senior Vice President, Finance | Sell | 4K | $20.81 | $83K | 52K |
| 2026-02-02 | WILLIAMS KRISTEN | Chief Administrative Officer | Sell | 13K | $20.53 | $270K | 131K |
| 2026-01-30 | RIKER LAUREN | Senior Vice President, Finance | Tax withholding | 3K | $20.54 | $57K | 56K |
| 2026-01-30 | WILLIAMS KRISTEN | Chief Administrative Officer | Tax withholding | 17K | $20.54 | $352K | 144K |
| 2026-01-30 | SLONIN JONATHAN | Chief Medical Officer | Tax withholding | 6K | $20.54 | $127K | 172K |
| 2026-01-30 | Teehan Brendan | Chief Commercial Officer | Tax withholding | 5K | $20.54 | $106K | 49K |
| 2026-01-30 | Lee Frank D. | Chief Executive Officer | Tax withholding | 41K | $20.54 | $852K | 399K |
| 2026-01-05 | RIKER LAUREN | Senior Vice President, Finance | Sell | 1K | $24.24 | $34K | 59K |
| 2026-01-02 | SLONIN JONATHAN | Chief Medical Officer | Tax withholding | 381 | $24.46 | $9K | 179K |
| 2026-01-02 | RIKER LAUREN | Senior Vice President, Finance | Tax withholding | 159 | $24.46 | $4K | 60K |
| 2026-01-02 | Lee Frank D. | Chief Executive Officer | Tax withholding | 9K | $24.46 | $227K | 441K |
| 2025-12-31 | Teehan Brendan | Chief Commercial Officer | Grant | 402 | $10.76 | $4K | 54K |
| 2025-12-31 | Teehan Brendan | Chief Commercial Officer | Grant | 402 | $10.76 | $4K | 54K |
| 2025-12-10 | Cross Shawn | Chief Financial Officer | Sell | 9K | $25.14 | $229K | 56K |
| 2025-12-10 | Cross Shawn | Chief Financial Officer | Exercise or conversion | 9K | $16.45 | $150K | 65K |
| 2025-12-09 | Cross Shawn | Chief Financial Officer | Sell | 16K | $25.03 | $398K | 56K |
| 2025-12-09 | Cross Shawn | Chief Financial Officer | Exercise or conversion | 16K | $16.45 | $261K | 72K |
| 2025-11-17 | SLONIN JONATHAN | Chief Medical Officer | Sell | 4K | $24.09 | $95K | 178K |
| 2025-11-10 | Cross Shawn | Chief Financial Officer | Sell | 12K | $22.09 | $266K | 56K |
| 2025-10-31 | Cross Shawn | Chief Financial Officer | Tax withholding | 7K | $21.38 | $143K | 68K |
| 2025-09-04 | Ceesay Abraham | Director | Sell | 2K | $27.19 | $64K | 9K |
| 2025-08-07 | BIGAL MARCELO | Director | Sell | 5K | $23.67 | $116K | 11K |
| 2025-08-01 | SLONIN JONATHAN | Chief Medical Officer | Tax withholding | 315 | $22.07 | $7K | 182K |
| 2025-06-11 | Kronenfeld Mark A. | Director | Grant | 6K | $0.00 | $0 | 31K |
| 2025-06-11 | YANG MICHAEL J. | Director | Grant | 6K | $0.00 | $0 | 13K |
| 2025-06-11 | Young Alethia | Director | Grant | 6K | $0.00 | $0 | 11K |
| 2025-06-11 | Kronenfeld Mark A. | Director | Grant | 10K | $0.00 | $0 | 35K |
| 2025-06-11 | Froimson Mark | Director | Grant | 6K | $0.00 | $0 | 21K |
| 2025-06-11 | Ceesay Abraham | Director | Grant | 6K | $0.00 | $0 | 11K |
| 2025-06-11 | CHRISTIE CHRISTOPHER | Director | Grant | 6K | $0.00 | $0 | 17K |
| 2025-06-11 | Brege Laura | Director | Grant | 6K | $0.00 | $0 | 24K |
| 2025-06-11 | BIGAL MARCELO | Director | Grant | 6K | $0.00 | $0 | 16K |
| 2025-06-04 | WILLIAMS KRISTEN | Chief Administrative Officer | Sell | 14K | $26.24 | $377K | 162K |
| 2025-06-04 | RIKER LAUREN | Senior Vice President, Finance | Sell | 6K | $26.21 | $146K | 60K |
| 2025-06-03 | SLONIN JONATHAN | Chief Medical Officer | Tax withholding | 5K | $26.40 | $134K | 182K |
| 2025-06-03 | WILLIAMS KRISTEN | Chief Administrative Officer | Tax withholding | 6K | $26.40 | $163K | 176K |
| 2025-06-03 | RIKER LAUREN | Senior Vice President, Finance | Tax withholding | 3K | $26.40 | $89K | 65K |
| 2025-02-01 | RIKER LAUREN | Senior Vice President, Finance | Grant | 31K | $0.00 | $0 | 69K |
| 2025-02-01 | Teehan Brendan | Chief Commercial Officer | Grant | 54K | $0.00 | $0 | 54K |
| 2025-02-01 | Lee Frank D. | Chief Executive Officer | Grant | 350K | $0.00 | $0 | 448K |
| 2025-02-01 | WILLIAMS KRISTEN | Chief Administrative Officer | Grant | 79K | $0.00 | $0 | 182K |
| 2025-02-01 | SLONIN JONATHAN | Chief Medical Officer | Grant | 94K | $0.00 | $0 | 187K |
| 2025-01-06 | SLONIN JONATHAN | Chief Medical Officer | Sell | 879 | $18.40 | $16K | 93K |
| 2025-01-02 | RIKER LAUREN | Senior Vice President, Finance | Tax withholding | 159 | $18.33 | $3K | 38K |
| 2025-01-02 | SLONIN JONATHAN | Chief Medical Officer | Tax withholding | 371 | $18.33 | $7K | 94K |
| 2025-01-02 | Lee Frank D. | Chief Executive Officer | Tax withholding | 9K | $18.33 | $172K | 98K |
| 2024-12-31 | GAUGLER DARYL | Chief Operating Officer | Grant | 244 | $16.01 | $4K | 115K |
| 2024-12-13 | GAUGLER DARYL | Chief Operating Officer | Sell | 500 | $19.76 | $10K | 115K |
| 2024-11-01 | Cross Shawn | Chief Financial Officer | Grant | 75K | $0.00 | $0 | 75K |
| 2024-09-13 | GAUGLER DARYL | Chief Operating Officer | Sell | 500 | $12.86 | $6K | 116K |
| 2024-08-16 | Brege Laura | Director | Buy | 1K | $12.81 | $13K | 18K |
| 2024-08-16 | BIGAL MARCELO | Director | Buy | 2K | $13.25 | $20K | 10K |
| 2024-08-14 | YANG MICHAEL J. | Director | Buy | 2K | $12.90 | $26K | 7K |
| 2024-08-12 | Froimson Mark | Director | Buy | 1K | $11.58 | $16K | 14K |
| 2024-08-12 | BIGAL MARCELO | Director | Buy | 3K | $12.01 | $41K | 9K |
| 2024-08-12 | Lee Frank D. | Chief Executive Officer | Buy | 8K | $12.10 | $100K | 108K |
| 2024-08-02 | SLONIN JONATHAN | Chief Medical Officer | Sell | 945 | $20.05 | $19K | 94K |
| 2024-08-01 | SLONIN JONATHAN | Chief Medical Officer | Tax withholding | 305 | $20.75 | $6K | 95K |
| 2024-07-02 | SLONIN JONATHAN | Chief Medical Officer | Sell | 3K | $28.25 | $80K | 96K |
| 2024-07-01 | SLONIN JONATHAN | Chief Medical Officer | Tax withholding | 914 | $28.46 | $26K | 98K |
| 2024-06-28 | SLONIN JONATHAN | Chief Medical Officer | Grant | 437 | $24.32 | $11K | 99K |
| 2024-06-28 | GAUGLER DARYL | Chief Operating Officer | Grant | 160 | $24.32 | $4K | 116K |
| 2024-06-13 | WILLIAMS KRISTEN | Chief Administrative Officer | Sell | 7K | $28.38 | $211K | 103K |
| 2024-06-13 | HASTINGS PAUL J | Director | Sell | 880 | $28.38 | $25K | 13K |
| 2024-06-13 | GAUGLER DARYL | Chief Operating Officer | Sell | 1K | $28.38 | $28K | 116K |
| 2024-06-12 | Kronenfeld Mark A. | Director | Grant | 5K | $0.00 | $0 | 25K |
| 2024-06-12 | Brege Laura | Director | Grant | 5K | $0.00 | $0 | 17K |
| 2024-06-12 | WILLIAMS KRISTEN | Chief Administrative Officer | Grant | 54K | $0.00 | $0 | 110K |
| 2024-06-12 | HASTINGS PAUL J | Director | Grant | 5K | $0.00 | $0 | 14K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON18 Form 144 notices on file for PCRX worth $3.0M at the prices reported; 2 in the last 90 days worth $289K. Latest: RIKER LAUREN filed on 2026-10-08 to sell 6,000 shares ($218K) from 2026-10-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-08 | RIKER LAURENOfficer | 6K | $218K | 0.015% | 2026-10-08 | Fidelity Brokerage Services LLC |
| 2026-08-17 | SLONIN JONATHANOfficer | 3K | $71K | 0.008% | 2026-08-17 | Fidelity Brokerage Services LLC |
| 2026-06-12 | Ceesay AbrahamDirector | 9K | $210K | 0.023% | 2026-06-12 | Fidelity Brokerage Services LLC |
| 2026-06-11 | RIKER LAURENOfficer | 6K | $144K | 0.016% | 2026-06-11 | Fidelity Brokerage Services LLC |
| 2026-06-04 | WILLIAMS KRISTENOfficer | 10K | $228K | 0.026% | 2026-06-04 | Fidelity Brokerage Services LLC |
| 2026-04-23 | Cross ShawnOfficer | 13K | $326K | 0.032% | 2026-04-23 | Fidelity Brokerage Services LLC |
| 2026-04-22 | Cross ShawnOfficer | 2K | $38K | 0.004% | 2026-04-22 | Fidelity Brokerage Services LLC |
| 2026-04-21 | Cross ShawnOfficer | 3K | $71K | 0.007% | 2026-04-21 | Fidelity Brokerage Services LLC |
| 2026-04-20 | Cross ShawnOfficer | 8K | $194K | 0.019% | 2026-04-20 | Fidelity Brokerage Services LLC |
| 2026-03-17 | SLONIN JONATHANOfficer | 3K | $74K | 0.008% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-03-17 | Froimson MarkDirector | 500 | $11K | 0.001% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-02-02 | RIKER LAURENOfficer | 4K | $84K | 0.009% | 2026-02-02 | Fidelity Brokerage Services LLC |
| 2026-02-02 | WILLIAMS KRISTENOfficer | 13K | $270K | 0.031% | 2026-02-02 | Fidelity Brokerage Services LLC |
| 2026-01-05 | RIKER LAURENOfficer | 1K | $34K | 0.003% | 2026-01-05 | Fidelity Brokerage Services LLC |
| 2025-12-10 | Cross ShawnOfficer | 9K | $229K | 0.021% | 2025-12-10 | Fidelity Brokerage Services LLC |
| 2025-12-09 | Cross ShawnOfficer | 16K | $398K | 0.037% | 2025-12-09 | Fidelity Brokerage Services LLC |
| 2025-11-17 | SLONIN JONATHANOfficer | 4K | $95K | 0.009% | 2025-11-17 | Fidelity Brokerage Services LLC |
| 2025-11-10 | Cross ShawnOfficer | 12K | $266K | 0.028% | 2025-11-10 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of PCRX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Portfolio Management at 6.4% of the class (2,585,964 shares), filed 2026-05-01 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-30 | 13G/Ano. 1 | Vanguard Capital Managementinvestment adviser | 1.9M | 4.8% | 2026-09-30 |
| 2026-10-13 | 13D/Ano. 4 | DOMA2 LLCother entity | 0 | 0.0% | 2026-10-08 |
| 2026-10-13 | 13D/Ano. 4 | The John Templeton Foundationcorporation | 0 | 0.0% | 2026-10-08 |
| 2026-10-13 | 13D/Ano. 4 | Pedro Escuderoindividual | 0 | 0.0% | 2026-10-08 |
| 2026-10-13 | 13D/Ano. 4 | DOMA Perpetual Partners GP LLCother entity | 0 | 0.0% | 2026-10-08 |
| 2026-10-13 | 13D/Ano. 4 | DOMA Perpetual LO Equity Master Fund LPpartnership | 0 | 0.0% | 2026-10-08 |
| 2026-10-13 | 13D/Ano. 4 | Doma Perpetual Capital Management LLCinvestment adviser | 0 | 0.0% | 2026-10-08 |
| 2026-10-13 | 13D/Ano. 4 | DOMA1 LLCother entity | 0 | 0.0% | 2026-10-08 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 2.1M | 5.2% | 2026-06-30 |
| 2026-05-01 | 13G | Vanguard Portfolio Managementinvestment adviser | 2.6M | 6.4% | 2026-03-31 |
| 2026-04-09 | 13G | Dimensional Fund Advisors LPinvestment adviser | 2.1M | 5.1% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 12 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-03-12 | 13D/Ano. 3 | Eric de Armasindividual | 1K | 0.0% | 2026-03-11 |
| 2026-01-02 | 13D/Ano. 2 | John Templeton Foundationcorporation | 812K | 1.9% | 2025-12-30 |
| 2025-11-13 | 13G/Ano. 1 | Renaissance Technologies LLCinvestment adviser | 2.1M | 5.0% | 2025-07-01 |
| 2025-11-13 | 13G/Ano. 1 | Renaissance Technologies Holdings Corporationparent holding company | 2.1M | 5.0% | 2025-07-01 |
13F holders
Tracked managers holding PCRX at their latest 13F. JSON6 of the 30 tracked managers held PCRX at their latest 13F, $126.0M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $49.5M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 2.0M | $49.5M | 0.02% | -32K |
| Renaissance Technologies | 2026-06-30 | 1.7M | $44.0M | 0.06% | -92K |
| Two Sigma Investments | 2026-06-30 | 725K | $18.4M | 0.01% | +198K |
| Millennium Management | 2026-06-30 | 235K | $6.0M | 0.00% | +178K |
| Citadel Advisors | 2026-06-30 | 162K | $4.1M | 0.00% | -635K |
| AQR Capital Management | 2026-06-30 | 159K | $4.0M | 0.00% | +4K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Pacira BioSciences reported revenue of $192.4M, up 6.2% from the same quarter a year earlier, and net income of $4.7M (0.12 diluted EPS). In FY 2025 it generated $152.0M of operating cash flow and spent $148.3M on buybacks. As of 2026-06-30, cash was $205.9M against $363.1M of debt.
- Cash
- $205.9M
- Debt
- $363.1M
- Equity
- $672.0M
- Total assets
- $1.24B
- Shares outstanding
- 39,861,886
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $192.4M | $4.7M | 2.4% | 0.12 |
| Q1 FY 2026 | 2026-03-31 | $177.4M | $2.9M | 1.6% | 0.07 |
| Q4 FY 2025derived | 2025-12-31 | $196.9M | $1.6M | 0.8% | n/a |
| Q3 FY 2025 | 2025-09-30 | $179.5M | $5.4M | 3.0% | 0.12 |
| Q2 FY 2025 | 2025-06-30 | $181.1M | -$4.8M | -2.7% | -0.11 |
| Q1 FY 2025 | 2025-03-31 | $168.9M | $4.8M | 2.8% | 0.10 |
| Q4 FY 2024derived | 2024-12-31 | $187.3M | $16.0M | 8.6% | n/a |
| Q3 FY 2024 | 2024-09-30 | $168.6M | -$143.5M | -85.1% | -3.11 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $726.4M | $7.0M | $152.0M | $15.3M | $148.3M | n/a |
| FY 2024 | 2024-12-31 | $701.0M | -$99.6M | $189.4M | $10.6M | $25.0M | n/a |
| FY 2023 | 2023-12-31 | $675.0M | $42.0M | $154.6M | $15.2M | $0 | n/a |
| FY 2022 | 2022-12-31 | $666.8M | $15.9M | $145.3M | $30.1M | $0 | n/a |
| FY 2021 | 2021-12-31 | $541.5M | $42.0M | $125.7M | $45.9M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Pacira BioSciences in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Pacira BioSciences (PCRX), SEC CIK 1396814, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-08.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1396814Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of PCRX is sold short?
4,260,076 shares were held short at the 2026-10-15 settlement, 1.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is PCRX's daily short volume?
On 2026-11-02, 76,191 of the 299,371 PCRX shares reported to FINRA were sold short, 25.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does PCRX have fails to deliver?
The SEC's latest file shows 16,029 PCRX shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are PCRX insiders buying or selling?
Insiders at PCRX reported 2 open-market sells worth $289K in the last 90 days and no open-market buys. Latest filing: RIKER LAUREN (Senior Vice President, Finance) on 2026-10-08.
Have PCRX insiders filed to sell?
18 Form 144 notices on file for PCRX worth $3.0M at the prices reported; 2 in the last 90 days worth $289K. Latest: RIKER LAUREN filed on 2026-10-08 to sell 6,000 shares ($218K) from 2026-10-08.
Who owns 5% or more of PCRX?
3 holders report 5% or more of PCRX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Portfolio Management at 6.4% of the class (2,585,964 shares), filed 2026-05-01 for an event on 2026-03-31.
What did PCRX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Pacira BioSciences reported revenue of $192.4M, up 6.2% from the same quarter a year earlier, and net income of $4.7M (0.12 diluted EPS). In FY 2025 it generated $152.0M of operating cash flow and spent $148.3M on buybacks. As of 2026-06-30, cash was $205.9M against $363.1M of debt.
Which tracked 13F managers own PCRX?
6 of the 30 tracked 13F managers held PCRX shares at their latest filing, $126.0M in all. The largest: D. E. Shaw & Co. (2.0M shares, $49.5M), Renaissance Technologies (1.7M shares, $44.0M), Two Sigma Investments (725K shares, $18.4M), Izzy Englander's Millennium Management (235K shares, $6.0M), Ken Griffin's Citadel Advisors (162K shares, $4.1M), Cliff Asness's AQR Capital Management (159K shares, $4.0M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.